Understanding “Delivering Dollars to the American People”: What Consumer-Driven Healthcare Really Means
As healthcare costs continue to shape political debates ahead of the 2026 midterm elections, the phrase “delivering dollars to the American people” has resurfaced as a central theme in Republican healthcare policy discussions. Framed as a consumer-driven approach, the idea centers on shifting financial responsibility from insurers and providers directly to individuals through mechanisms like health savings accounts (HSAs) and high-deductible health plans (HDHPs). Proponents argue that when patients control their own healthcare dollars, they become more discerning consumers, driving competition and lowering prices. Yet, decades of health economics research suggest the reality is more complex.
The concept is not fresh. Since the early 2000s, policymakers have promoted consumer-directed models as a way to increase transparency and reduce spending. Yet empirical evidence consistently shows that simply giving patients more financial skin in the game does not reliably lead to smarter shopping or better value. Instead, studies reveal that patients often lack the information, tools, and market power needed to make informed choices—especially when physicians exert strong influence over treatment decisions or when healthcare markets are highly consolidated.
To understand whether this approach can truly deliver on its promise, it’s essential to examine both the theoretical underpinnings and real-world outcomes of consumer-driven healthcare. From Kenneth Arrow’s foundational function on healthcare market inefficiencies to recent analyses of reference pricing and decision aids, the evidence points to a nuanced conclusion: patient engagement can improve care—but only when supported by robust infrastructure, accurate price transparency, and meaningful choice.
The Economic Theory Behind Consumer-Driven Healthcare
The core assumption of consumer-driven healthcare is that patients, when given financial incentives, will behave like rational consumers in other markets—comparing prices, seeking value, and avoiding unnecessary care. This idea relies on standard economic principles of supply and demand. However, in 1963, Nobel laureate Kenneth Arrow identified fundamental reasons why healthcare markets deviate from this model. In his seminal paper, he argued that healthcare is unique due to uncertainty in outcomes, information asymmetry (where providers know more than patients), and the prevalence of emergency situations that prevent comparison shopping.
Arrow’s insights remain foundational in health economics. Subsequent research has built on this, particularly the concept of physician-induced demand—the idea that doctors’ recommendations, rather than patient preferences, often drive utilization. A 1992 study by Thomas Rice in the Journal of Health Economics questioned whether patient demand for care exists independently of physician influence, finding strong evidence that clinical judgment shapes patient decisions more than price sensitivity.
More recent work confirms that even when patients are motivated to save money, they frequently defer to their doctors. A 2013 National Bureau of Economic Research (NBER) study analyzed patient choices for lower-limb MRI scans and found that individuals bypassed an average of six lower-priced facilities to use the provider recommended by their physician. This suggests that trust in medical expertise often outweighs cost considerations, undermining the premise that financial incentives alone will drive price-sensitive behavior.
What the Evidence Shows: Mixed Results from HDHPs and HSAs
Empirical evaluations of high-deductible health plans and health savings accounts reveal a pattern of reduced utilization—but not necessarily smarter spending. A 2017 systematic review published in Health Affairs by Rajender Agarwal and colleagues found that HDHPs are associated with lower overall costs, primarily because patients use fewer services across the board. Concerningly, this reduction included preventive care and chronic disease medications, raising alarms about potential long-term health consequences.
Further evidence comes from a 2025 Government Accountability Office (GAO) report, which found that HSAs disproportionately enroll healthier and wealthier individuals. The report noted that higher-income beneficiaries are more likely to contribute the maximum allowed to their accounts and to invest unused funds, whereas lower-income enrollees often struggle to afford even basic out-of-pocket costs. This raises equity concerns: rather than empowering all consumers, consumer-driven models may advantage those already financially secure.
When it comes to actual price effects, data remains limited. A 2013 study by Neeraj Sood and colleagues, published in Frontiers in Health Policy and Economics, examined payments for nine outpatient procedures across 63 large employer plans. The researchers found no significant association between enrollment in consumer-driven plans and lower prices—except for a modest 2.3% reduction in average costs for office visits. These findings suggest that without structural tools to support comparison shopping, financial incentives alone have little impact on market pricing.
Reference Pricing and Decision Aids: Where Incentives Work
While pure consumer-driven models have underperformed, certain hybrid approaches show promise. Reference pricing—a strategy where insurers set a benchmark price for a service and cover costs up to that amount—has demonstrated measurable success when combined with decision support tools. For example, the California Public Employees’ Retirement System (CalPERS) implemented reference pricing for knee and hip replacements in 2009, leading to a significant shift in patient volume toward lower-cost providers.
Similarly, a 2016 study in Medical Care found that reference pricing applied to imaging services reduced CT scan prices by 12.5% and MRI prices by 10.5% among Safeway employees. The same approach has been used effectively for colonoscopies, ambulatory surgery, and laboratory testing. Crucially, these programs succeeded not just because of financial incentives, but because they included decision aids—structured resources that provided patients with clear information on prices, quality ratings, and provider options.
A 2020 Cochrane review of 71 patient decision aids confirmed their value in helping individuals make choices aligned with their preferences, particularly for elective surgeries and chronic disease treatments. However, the review also noted that most aids do not include real-time pricing data, which changes frequently and would require constant updating to remain useful. Adding cost transparency to decision aids is technically feasible but increases complexity and maintenance costs.
Structural Barriers: Consolidation and Limited Choice
Even with the best intentions, consumer-driven strategies face a fundamental obstacle: lack of meaningful competition. In many geographic markets, hospital systems and physician groups have consolidated to the point where patients have few, if any, alternatives. According to data from the Kaiser Family Foundation (KFF), over 80% of metropolitan areas in the U.S. Are characterized by high levels of hospital market concentration, limiting the potential for price competition regardless of patient motivation.
This consolidation reduces the effectiveness of any policy that relies on consumers “shopping around.” When there is only one major provider within a reasonable distance, or when all local hospitals charge similar high prices, giving patients more financial responsibility simply increases their burden without enabling better choices. In such environments, utilization review, network design, and performance-based payments—strategies that target suppliers rather than consumers—may be more effective at promoting value.
Who Is Affected and What It Means for Voters
The impact of consumer-driven healthcare varies significantly across populations. Healthier, higher-income individuals tend to benefit most from HSAs, as they can absorb higher deductibles and seize advantage of tax-advantaged savings. In contrast, patients with chronic conditions, low incomes, or limited health literacy often avoid necessary care due to cost fears, leading to delayed diagnoses and worse outcomes.
Employers, too, have adopted HDHPs widely as a cost-containment strategy, shifting more of the financial risk onto employees. While this has helped moderate premium growth, it has also increased out-of-pocket spending, with the average deductible for individual coverage now exceeding $1,700 in employer-sponsored plans, according to KFF’s 2024 Employer Health Benefits Survey.
For voters evaluating competing healthcare visions, the key question is not whether consumer engagement has value—it clearly does—but whether giving patients more financial control, without addressing information gaps, market power imbalances, or provider influence, will actually lower costs and improve care. The evidence suggests it will not, unless paired with stronger supports.
Looking Ahead: What Voters Should Watch For
As Congress prepares for potential healthcare debates in 2025 and 2026, several developments merit attention. The Biden administration has continued to enforce price transparency rules requiring hospitals to publish negotiated rates, though compliance remains uneven. Meanwhile, some states are experimenting with reference pricing in public employee health plans, and federal agencies are evaluating ways to improve the usability of decision aids.
No major federal consumer-driven healthcare legislation has been introduced as of mid-2025, but policy white papers and campaign rhetoric indicate that the concept remains influential in conservative circles. Any future proposal should be evaluated not just on its ideological appeal, but on its alignment with evidence about what actually works to improve value in healthcare.
For reliable updates, voters can refer to nonpartisan sources such as the Congressional Budget Office (CBO) for cost estimates, the Kaiser Family Foundation for polling and policy analysis, and the Agency for Healthcare Research and Quality (AHRQ) for evidence on care delivery models.
Healthcare policy affects everyone. As the debate continues, informed discussion grounded in research—not rhetoric—will be essential to shaping solutions that are both fiscally responsible and equitable.